Abstract: The present invention relates nanoparticles formed of a polymer and an antifungal agent, wherein the polymer is selected from the group consisting of linear or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogues or derivatives thereof, or mixtures thereof. The nanoparticles are particularly suited for the treatment of fungal nail or skin infections.

Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.

Abstract: The present invention relates nanoparticles formed of a polymer and an antifungal agent, wherein the polymer is selected from the group consisting of linear or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogues or derivatives thereof, or mixtures thereof. The nanoparticles are particularly suited for the treatment of fungal nail or skin infections.

Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.

Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.

Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.

Abstract: The present invention is directed to oligonucleotides based on peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences and the use of such oligonucleotides for the dissociation of higher order structures, including triplex-helix DNA structures, in repeated sequences of DNA in Friedreich's ataxia. The dissociation of such structures may be used in the diagnosis and/or treatment of Friedreich's ataxia. Consequently, the present invention is also directed to a method for diagnosing Friedreich's ataxia and the use of peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences in the treatment of Friedreich's ataxia. Preferably, the oligonucleotides comprise a sequence selected from the group consisting of (GAA)n, (CTT)n, (JTT)n or a mixed (JTT/CTT)n sequence.

Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.

Abstract: The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2.

Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.

Abstract: This invention relates to vector sequences that express growth inhibitory levels of essential genes used in combination with inhibitors that target the same gene. An example given is the use of the gene encoding the fatty acid biosynthesis enzyme enoyl-ACP reductase used in combination with the antimicrobial triclosan. The expression level of the enoyl-ACP reductase is sufficient to suppress the toxic effects of triclosan and the triclosan is used at levels that are sufficient to suppress the toxic effects of the enoyl-ACP reductase. The invention provides methods to enhance the growth and survival of genetically modified organisms and to increase the production and expression of plasmid vectors in the presence of triclosan, relative to methods that rely on antibiotics and antibiotic resistance markers. Also, the invention provides methods to limit the spread of genetically modified organisms.

Abstract: This invention relates to compounds, compositions, and methods useful for modulating the expression and activity of NF-kappa-B by RNA interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA) and double-stranded RNA (dsRNA). Furthermore the invention provides methods for preventing, treating or alleviating NF-kappa-B dependent diseases whereby NF-kappa-B is believed to play a role in the pathogenesis of a disease in a subject, preferably a human, by administration of a therapeutic effective and in a pharmacologically accepted form, the siRNA compounds of the invention.

Abstract: The present invention relates antisense oligonucleotide compounds for use in modulating the function of nucleic acid molecules encoding neutrophil gelatinase associated lipocalin (NGAL). More specifically, the invention provides compounds of 8 to 50 nucleobases in length capable of specifically hybridising with nucleic acid molecules encoding NGAL and thereby inhibiting the expression of the NGAL protein product, as well as pharmaceutical compositions thereof and methods of their use.

Abstract: Methods of and compositions for killing or inhibiting the growth of a bacteria are disclosed. The methods comprise the use of peptide nucleic acids that are targeted to mRNA and/or rRNA. In certain embodiments, methods include the use of one or more separate antibiotics.

Abstract: The present invention relates antisense oligonucleotide compounds for use in modulating the function of nucleic acid molecules encoding mammalian MMP-12. More specifically, the invention provides compounds of 8 to 50 nucleobases in length capable of specifically hybridising with nucleic acid molecules encoding MMP-12 and thereby inhibiting the expression of the MMP-12 protein product, as well as pharmaceutical compositions thereof and methods of its use.

Abstract: The present invention relates to novel drugs which may be used in combating infectious micro-organisms, particularly bacteria.

Abstract: The present invention relates to novel drugs which may be used in combating infectious micro-organisms, particularly bacteria.

Abstract: The present invention relates to novel drugs which may be used in combating infectious micro-organisms, particularly bacteria. More specifically, the invention relates to peptide nucleic acid (PNA) sequences that are modified by conjugating cationic peptides to the PNA moiety in order to obtain novel PNA molecules that exhibit enhanced anti-infective properties.

Abstract: Methods of and compositions for killing or inhibiting the growth of a bacteria are disclosed. The methods comprise the use of peptide nucleic acid that is targeted to mRNA and/or rRNA. In certain embodiments, methods include the use of one or more separate antibiotics.

Abstract: Methods of and compositions for killing or inhibiting the growth of a bacteria are disclosed. Methods of determing bacterial gene functions are also disclosed. The methods comprise the use of peptide nucleic acid that is targeted to mRNA and/or rRNA. In certain embodiments, methods include the use of one or more separate antibiotics.